Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00507728 · ClinicalTrials.gov registry record · Phase 2
Pharmacogenetics, Emotional Reactivity and Smoking
A Phase 2 study of Smoking Cessation and Tobacco Use Disorder, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 646
- Enrollment target
- 1
- Study location
NCT00507728: Completed Phase 2 study of Smoking Cessation and Tobacco Use Disorder, sponsored by M.D. Anderson Cancer Center.
NCT00507728 is a Phase 2 study of Smoking Cessation and Tobacco Use Disorder that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 646 participants, above the 471-participant average among 188 other Smoking Cessation trials with a reported enrollment target (37% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00507728, a Phase 2 study of Smoking Cessation and Tobacco Use Disorder, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 646 participants
- Enrollment target
- 1
- Study location
Study Summary
The goals of this placebo-controlled randomized clinical trial were to evaluate the differences in emotional reactivity (peak startle response to affective stimuli) during a cessation attempt among smokers treated with bupropion, varenicline, or placebo, and to determine if these differences were moderated by genotype.
Primary Outcome
Emotional reactivity measured by the peak eye blink electromyography (EMG) of the orbicularis oculi (ORB) muscle responses to acoustic startle probe delivered during the presentation of emotionally valent stimuli (pleasant, unpleasant, neutral, and smoking-related pictures). A single value was estimated by averaging within the specific time interval.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Varenicline
- BEHAVIORAL Smoking Cessation Counseling
- DRUG Bupropion
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 646 participants |
| Start Date | 2005-12-08 |
| Est. Completion | 2019-12-18 |
| Phase | Phase 2 |
What the finished NCT00507728 record still lists
NCT00507728 is an interventional study that assigns participants to a tested intervention. The registered 646 participants enrollment target is mid-sized for trials with a published cap, above the 471-participant average among 188 other Smoking Cessation trials with a reported enrollment target (37% higher).
The record links to 2 conditions, with Smoking Cessation appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT00507728 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00507728 about?
NCT00507728 is a clinical study titled "Pharmacogenetics, Emotional Reactivity and Smoking". The goals of this placebo-controlled randomized clinical trial were to evaluate the differences in emotional reactivity (peak startle response to affective stimuli) during a cessation attempt among smokers treated with bupropion, varenicline, or placebo, and to determine if these differences were mo...
What is the current status of trial NCT00507728?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 646 participants. The study started on 2005-12-08. Estimated completion is 2019-12-18.
What conditions does trial NCT00507728 study?
This clinical trial studies the following conditions: Smoking Cessation, Tobacco Use Disorder.
What interventions are being tested in trial NCT00507728?
The interventions under investigation include: Placebo (DRUG), Varenicline (DRUG), Smoking Cessation Counseling (BEHAVIORAL), Bupropion (DRUG).
Who is sponsoring clinical trial NCT00507728?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00507728 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00507728's enrollment target sits among peer trials
646 41st of 188 higher than 148 of 188 other Smoking Cessation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity
RECRUITING · Phase 2
-
Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study
RECRUITING · Phase 2
-
Proof-Of-Concept Investigation With a Neurosteroid Analog (Ganaxolone) as a Smoking Cessation Candidate
COMPLETED · Phase 2
-
Treating Smokers With Mental Illness
COMPLETED · Phase 2
-
Suvorexant to Reduce Symptoms of Nicotine Use
COMPLETED · Phase 2
-
Provoked Craving Relief Study by NRT
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04863222 · 646 participants · Phase 4
Clinical and Radiographic Success of MTA vs Biodentine
- NCT07012395 · 645 participants · Phase 2
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
- NCT07027306 · 648 participants
The Osteoporotic Fracture Classification-based Scoring System for Treatment Decision in Thoracolumbar Osteoporotic Fractures
- NCT07164456 · 648 participants · NA
Together Stronger: A Family-centered Lifestyle Intervention for Black Prostate Cancer Survivors and Their Caregivers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI